LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Search

Adverum Biotechnologies Inc

Gesloten

SectorGezondheidszorg

4.29 0.23

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.29

Max

4.29

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+132.39% upside

Nieuwssentiment

By Acuity

84%

16%

358 / 374 Rangschikking in Healthcare

Adverum Biotechnologies Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 okt 2025, 13:04 UTC

Acquisities, Fusies, Overnames

Eli Lilly Agrees to Acquire Adverum Biotechnologies

24 okt 2025, 12:34 UTC

Acquisities, Fusies, Overnames

Eli Lilly Says Transaction Is Expected to Close in the 4Q >LLY

24 okt 2025, 12:34 UTC

Acquisities, Fusies, Overnames

Eli Lilly: Offer Also Includes 1 Non-Transferrable Contingent Value Right Entitling Holder to Receive Up to an Additional $8.91 Per CVR in Cash Upon the Achievement of 2 Milestones, for Total Potential Consideration of Up to $12.47/Shr >LLY

24 okt 2025, 12:33 UTC

Acquisities, Fusies, Overnames

Eli Lilly to Launch Tender Offer to Acquire All Outstanding Shares of Adverum for $3.56/Shr >LLY

24 okt 2025, 12:30 UTC

Acquisities, Fusies, Overnames

Lilly To Acquire Adverum Biotechnologies >LLY ADVM

Peer Vergelijking

Prijswijziging

Adverum Biotechnologies Inc Prognose

Koersdoel

By TipRanks

132.39% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 9.9 USD  132.39%

Hoogste 30 USD

Laagste 4 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Adverum Biotechnologies Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

3

Buy

3

Hold

0

Sell

Sentiment

By Acuity

358 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

$

help-icon Live chat